

ダパグリフロジンは駆出率の低下した患者に有益である (Abstract 19-LB-20165)

DECLARE-TIMI 58: 糖尿病治療薬は広範な心不全に対し有効である

DECLARE-TIMI 58: Diabetes drug effective against heart failure in wide spectrum of patients

糖尿病治療薬ダパグリフロジンの心血管系に対する有益性は広範な患者に認められ、特に駆出率の低下した患者において顕著である、と American College of Cardiology's 68th Annual Scientific Session で発表され、同時に *Circulation* に掲載された。研究者らは、ダパグリフロジンが駆出率やスタディ開始時の心不全の有無に関係なく、全ての患者を通じて心不全による入院を減少させたことを明らかにした。しかし、この薬剤が心血管死亡率および総死亡率を有意に減少させたのは、駆出率の低下した患者においてのみであった。この結果は DECLARE-TIMI 58 から得られたものである。

Full Text

The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of patients and are especially pronounced in those with reduced ejection fraction according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

The findings stem from the DECLARE-TIMI 58 trial, which reported in 2018 that dapagliflozin, part of a class of drugs known as SGLT2 inhibitors, reduced the composite primary endpoint of cardiovascular death and heart failure hospitalizations, which was mainly driven by the reduction in hospitalization for heart failure. The new analysis is the first to examine whether dapagliflozin's benefits can be predicted based on left ventricular ejection fraction (LVEF), a measure of how effectively the heart's left ventricle squeezes blood out of its chamber.

Low ejection fraction can be evidence of heart failure, though many patients have heart failure with normal, or preserved, ejection fraction. Researchers found dapagliflozin decreased heart failure hospitalizations across all patients, regardless of ejection fraction or whether or not they had heart failure at the start of the study. However, the drug significantly decreased rates of death from cardiovascular causes and death from all causes only among those who had a lower ejection fraction.

"The use of the SGLT2 inhibitor dapagliflozin is beneficial in reducing hospitalizations for heart failure in patients with a broad range of left ventricular ejection fraction, but patients with reduced ejection fraction may derive an even greater benefit," said Eri T. Kato, MD, PhD, a cardiologist at Kyoto University Hospital and the study's lead author. "The clinical implication of this finding is that ejection fraction is a strong tool to identify those who are at highest risk and may derive particular benefit from SGLT2 inhibitors."

SGLT2 inhibitors improve the body's ability to remove glucose from the bloodstream, helping to regulate blood sugar in people with diabetes. DECLARE-TIMI 58, conducted at 882 sites in 33 countries, enrolled more than 17,000 patients who had Type 2 diabetes, as well as either established cardiovascular disease or a high risk for cardiovascular disease. Patients were randomized to receive dapagliflozin or a placebo and followed for a median of just over four years.

Thirty percent of study participants (5,202 patients) had their LVEF documented at the start of the trial. Of these participants, 13 percent (671 patients) had heart failure with reduced ejection fraction (HFrEF), defined as an ejection fraction less than 45 percent, meaning that just 45 percent of the blood in the left ventricle is squeezed out with each heartbeat.

Researchers compared rates of heart failure hospitalizations, cardiovascular death and all-cause mortality among patients with HFrEF and those without HFrEF. They found patients with HFrEF who took dapagliflozin were 38 percent less likely to be hospitalized for heart failure or die of cardiovascular causes compared with those taking placebo, a significantly greater reduction than the 12 percent drop in the likelihood of these events among patients who did not have HFrEF.

Patients who had HFrEF also showed a significantly lower rate of cardiovascular death and death from any cause, rates of which dropped by 45 percent and 41 percent, respectively, among those taking dapagliflozin compared to those taking placebo. Researchers did not observe these benefits in patients without HFrEF. Taking dapagliflozin reduced the rate of heart failure hospitalizations among all patients, regardless of ejection fraction or heart failure status.

"The reduction in hospitalization for heart failure is remarkable because there have been very few therapies that have shown any benefit both in patients with heart failure with preserved ejection fraction and in patients with heart failure with reduced ejection fraction," Kato said. "Furthermore, there appears to be a benefit for heart failure reduction across a broad spectrum of patients with and without heart failure, suggesting that use of these agents could be beneficial in a very large population of patients with diabetes."

Patients who have heart failure with reduced ejection fraction generally face a higher risk for cardiovascular events and death compared to those with normal ejection fraction. In the trial, these patients also showed a benefit from dapagliflozin in terms of heart failure hospitalizations earlier than the other groups, while the benefits took a year or more to appear in other groups. Noting that the interplay between diabetes and heart failure is complex and multifactorial, Kato said further studies are needed to understand the mechanisms driving these differences.

Researchers plan to further analyze the DECLARE-TIMI 58 data to understand dapagliflozin's effects on metabolic, renal and cardiovascular outcomes. Other ongoing trials are investigating SGLT2 inhibitors in patients with heart failure, which should shed further light on the benefits observed in this study, Kato said.

DECLARE-TIMI 58 was funded by AstraZeneca.

This study was simultaneously published online in *Circulation* at the time of presentation.

ACC2019特集

[News01]

糖質制限ダイエットは心房細動に関連する

[News02]

フィットネスレベルが高いほど高齢者の寿命を延ばす可能性がある

[News03]

外科手術リスクの低い患者に対するTAVRは外科手術と同様に優れている

[News04]

二尖弁性大動脈弁狭窄に対する治療選択肢は開心術のみではない

[News05]

ベンパド酸は12週後のLDLコレステロールを低下させる

[News06]

AFibとACSを有する患者に対するアスピリンを用いない2剤併用療法は最も安全である

[News07]

生体吸収性エンベロープはデバイス関連感染症を減少させる

[News08]

ダパグリフロジンは駆出率の低下した患者に有益である

[News09]

ステント留置後の患者においてDAPTを中止することにより予後が改善する

[News10]

PCIにおける橈骨動脈アプローチと大腿動脈アプローチとは生存率に関しては同等である

[News11]

心内膜炎に対する抗菌薬の経口投与への切り替えは失敗ではない

[News12]

進行した心不全において新たなLVADは転帰をより良好にする

[News13]

高純度オメガ3製剤は心血管イベントを著明に減少させる

[News14]

閉鎖不全を有する弁の修復はQOLを改善する

[News15]

全ての心停止に対し緊急のインターベンションが必要なわけではない

[News16]

CardioMEMSセンサーは入院を半分以上に減少させる

[News17]

高齢者において降圧は脳損傷の悪化を予防する